Phase 2 Autologous Stem Cell Transplant Clinical Trials
6 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–6 of 6 trials
Recruiting
Phase 2
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
Classic Hodgkin LymphomaAutologous Stem Cell Transplant
Masonic Cancer Center, University of Minnesota28 enrolled1 locationNCT06377540
Recruiting
Phase 2
High Heated Humidity in Stem Cell Transplant
Autologous Stem Cell Transplant
AHS Cancer Control Alberta90 enrolled1 locationNCT05358262
Recruiting
Phase 2
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
Lymphoma, B-CellAutologous Stem Cell Transplantation
The First Affiliated Hospital of Soochow University64 enrolled1 locationNCT06381830
Completed
Phase 2
Panobinostat maintenance in patients with multiple myeloma that have achieved less than complete remission following autologous stem cell transplantation.
Multiple myeloma less than complete remission following Autologous Stem Cell Transplant
The Alfred Hospital25 enrolled1 locationACTRN12613000219785
Recruiting
Phase 2
A phase II study of lenalidomide and prednisolone as post-autologous stem cell transplant (ASCT) maintenance therapy for patients with Multiple Myeloma incorporating residual disease monitoring.
Residual Multiple Myeloma in patients post autologous stem cell transplant.
Malignant haematology and stem cell transplant Service40 enrolled1 locationACTRN12611000597998
Completed
Phase 2
A multi-centre phase II trial of early treatment intensification with R-ICE (rituximab – ifosfamide, carboplatin, etoposide) chemotherapy followed by BEAM ( BCNU(BCNU is Carmustine), etoposide, ara-C (ara-C is Cytarabine), melphalan) high dose chemotherapy and autologous stem cell transplantation for patients with poor prognosis diffuse large B-cell lymphoma
Patients with CD20+ diffuse large B cell lymphoma (DLBCL) with low intermediate, high intermediate, or high risk disease or low risk disease with bulky tumour (> 7.5 cm) who are considered fit and eligible for high dose chemotherapy (HDCT) with Z-BEAM ( Zevalin - BEAM ( BCNU(BCNU is Carmustine), etoposide, ara-C (ara-C is Cytarabine), melphalan) and autologous stem cell transplantation (ASCT).
Australasian Leukaemia and Lymphoma Group (ALLG)162 enrolled1 locationACTRN12609001077257